You are here:  Home  >  News  >  Business  >  Current Article

Aurion Biotech Announces IOTA Cell Therapy Trial

By   /  July 26, 2021  /  Comments Off on Aurion Biotech Announces IOTA Cell Therapy Trial

    Print       Email

SEATTLE & BOSTON & TOKYO–()–Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases, today announced preliminary findings from its IOTA trial, conducted in November 2020 and in May of this year, at the Clínica Quesada in San Salvador, El Salvador.

In the IOTA trial, 50 patients diagnosed with corneal endothelial disease were treated with a transformational cell therapy procedure first developed by Professor Shigeru Kinoshita and colleagues at Kyoto Prefecture University of Medicine (KPUM). The IOTA trial is the first corneal endothelial cell therapy procedure to be performed successfully outside of Japan, with Drs. Gabriel and…

Click here to view the original article.

    Print       Email

You might also like...

IACC Holdings Certified as a Best Place to Work in Egypt for 2021

Read More →